Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial
Reported by Economic Times Industry, not nibnow. We are not the publisher of this story, only the source is.
The trial showed most patients had a sharp drop in PSA levels and tumor shrinkage, suggesting the drug could become a new option for advanced prostate cancer that has resisted other treatments.
Johnson & Johnson reported results from an early-stage trial of their prostate cancer drug JNJ-6143. The trial involved patients with advanced prostate cancer who had undergone multiple treatments. Results showed 77% of patients experienced a significant drop in PSA levels after treatment. Additionally, 69% of patients demonstrated confirmed partial or complete tumor response through imaging. Common side effects included nausea and elevated cholesterol levels, with one patient discontinuing trea
Prostate-specific antigen (PSA) is a blood marker used to monitor prostate cancer activity, and reductions often indicate treatment effectiveness. Early-stage trials test safety and early signals of efficacy before larger, definitive studies are conducted.
- •Results from planned Phase 3 trials to confirm efficacy and safety
- •Regulatory submissions or approvals if later-stage data are positive
- •Potential updates on side‑effect management, especially cholesterol changes